patritumab
daiichi sankyo
['patritumab', 'sclc', 'lcsm,(-blcsm)', 'nsclc']
while we need to learn more about patritumab-deruxtecan, exciting to see activity outside egfrm and even in heavily pretreated nsclc without any activating mutations! #asco22 #lcsm 
Med onc and hematologist at @chudequebec with focus on lung cancer. Tweets in English for sake of conversation, mais toujours heureux de parler français!